Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial

Long-stay patients with severe schizophrenia are frequently treated with high doses of first-generation antipsychotics (FGA). Dose reduction or switching to ziprasidone may reduce the severity of negative symptoms and side effects.We investigated in a randomized double-blind trial whether a dose-reduction strategy to achieve an adequate dose of a FGA (5  mg/day haloperidol equivalents, n = 24) or switching to ziprasidone (160 mg/day, n = 24) in treatment resistant patients would decrease negative symptoms after 1 year of treatment.
Source: European Neuropsychopharmacology - Category: Psychiatry & Psychology Authors: Source Type: research

Related Links:

Publication date: 1 December 2019Source: Personality and Individual Differences, Volume 151Author(s): Steffen Moritz, Burghard Andresen, Mary SenguttaAbstractResearch on schizotypal personality and schizotypy has emerged as an important methodological alternative to the investigation of manifest schizophrenia. Contrary to the assumption that schizotypy/schizotypal personality is specifically associated with schizophrenia, some studies have shown that psychiatric controls at times achieve similar scores in schizotypy assessment tools to patients with schizophrenia. We compared patients with schizophrenia, depression, and ob...
Source: Personality and Individual Differences - Category: Psychiatry & Psychology Source Type: research
This week’s Psychology Around the Net has the latest on a new virtual reality therapy trial for people diagnosed with serious mental illnesses, how people with mental health disorders are helping amend their descriptions in diagnostic guidelines, the issues that stop you from setting boundaries and how you can overcome those issues, and more. People With Mental Health Disorders Amend the Descriptions: What would happen if input from people who actually deal with mental health disorders on a daily basis was taken into consideration when it comes to the diagnostic guidelines describing said disorders? A new study set ...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Psychology Around the Net Addiction Cannabis cannabis dependency cannabis treatment Loneliness Nhs Procrastination Productivity Psychosis Setting Boundaries Shame virtual reality Source Type: blogs
According to the neurodevelopmental hypothesis of schizophrenia, the premorbid stages of nonaffective psychosis are characterized by early phenotypic manifestations of neurobiological vulnerability, whose developmental trends are accurately characterized f...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
This study evaluated psychache and...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
ConclusionAlthough single-session tDCS did not improve illness awareness, this pilot study provides mechanistic justification for future investigations to determine if multi-session bi-parietal tDCS can induce sustained changes in brain activity in the PPA in association with improved illness awareness.
Source: European Psychiatry - Category: Psychiatry Source Type: research
Publication date: Available online 19 July 2019Source: Neurochemistry InternationalAuthor(s): Lauren Kosten, Golam M. Chowdhury, Susana Mingote, Steven Staelens, Douglas L. Rothman, Kevin L. Behar, Stephen RayportAbstractGlutaminase mediates the recycling of neurotransmitter glutamate, supporting most excitatory neurotransmission in the mammalian central nervous system. A constitutive heterozygous reduction in GLS1 engenders in mice a model of schizophrenia resilience and associated increases in Gln, reductions in Glu and activity-dependent attenuation of excitatory synaptic transmission. Hippocampal brain slices from GLS1...
Source: Neurochemistry International - Category: Neuroscience Source Type: research
This study investigated the relationship between the activities of daily living and the length of hospitalization to determine the optimal length of hospitalization for patients with schizophrenia. We collected information from all schizophrenia patients discharged in Peking University Huilongguan Clinical Medical School from January 1, 2015 to December 31, 2015. A total of 1967 patients were enrolled in this study. The Chinese version of the modified Barthel index (MBI-C) was used to assess patients ’ actual performance on activities of daily living. We used the paired samples t-test to compare MBI-C scores at admis...
Source: Psychiatric Quarterly - Category: Psychiatry Source Type: research
Authors: Citrome L, Zeni CM, Correll CU Abstract Transdermal delivery is an alternative to oral routes of drug administration and has made considerable contributions to the treatment of various medical diseases. With the advent of new transdermal delivery technologies, higher numbers of medications are being approved for use as transdermal formulations. This route of administration has several innate advantages that have the potential to benefit various patient populations, including those with central nervous system disorders. The current review briefly outlines the history of transdermal medications, discusses th...
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
In conclusion, SCZOff showed neurocognitive impairments in several neuropsychological domains compared to CCOff. Neuropsychological functioning, environmental factors and positive prodromal symptoms could predict the risk of onset of severe mental disorders in SCZOff. PMID: 31312885 [PubMed - as supplied by publisher]
Source: European Archives of Psychiatry and Clinical Neuroscience - Category: Psychiatry Tags: Eur Arch Psychiatry Clin Neurosci Source Type: research
Condition:   Schizophrenia Intervention:   Device: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System Sponsors:   ERP Biomarker Qualification Consortium;   COGNISION;   Cadent Therapeutics;   Alkermes, Inc.;   Anavex Life Sciences Corp.;   Merck Sharp & Dohme Corp.;   Takeda;   Sage Therapeutics;   H. Lundbeck A/S Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Clinical Trials | Geodon | Neurology | Psychology | Schizophrenia | Ziprasidone